tacrolimus and Foot-Dermatoses

Nail involvement in lichen striatus (LS) is rare and has not been documented extensively.. This study describes the clinical and histological features, response to treatment, and follow-up in seven patients with nail LS.. We reviewed seven cases of nail LS between 2006 and 2012 at the Dermatology Department, Yeouido St Mary's Hospital, Seoul, South Korea.. The median patient age was 11 years (range: 4-33 years), and the female:male ratio was 3:4. All patients had both typical skin lesions and nail abnormalities. In these cases, LS usually involved a single digit (n = 5). The most common nail change was longitudinal fissuring (n = 4). We actively treated both skin and nail lesions from the time of diagnosis. Most nail lesions resolved within a mean of four months of the initiation of treatment.. Nail involvement in LS is rare; this case series highlights the associated nail changes. We emphasize that early accurate diagnosis and treatment may be beneficial in reducing nail deformities in patients with nail involvement.

Topics: Adrenal Cortex Hormones; Adult; Child; Child, Preschool; Drug Therapy, Combination; Female; Foot Dermatoses; Hand Dermatoses; Humans; Immunosuppressive Agents; Lichenoid Eruptions; Male; Nail Diseases; Tacrolimus; Triamcinolone Acetonide

Topics: Administration, Topical; Child; Foot Dermatoses; Humans; Immunosuppressive Agents; Male; Tacrolimus

Acrodermatitis continua suppurativa of Hallopeau (ACS) is a rare pustular variant of psoriasis in which numerous treatment modalities have been used without any consistent long-term effect. We report for the first time two patients with ACS which was successfully treated with topical tacrolimus 0.1% ointment. Our observations raise hopes that this new treatment strategy for ACS may constitute a novel effective therapeutic option for this recalcitrant condition.

Topics: Acrodermatitis; Administration, Topical; Aged; Aged, 80 and over; Bandages; Drug Administration Schedule; Female; Foot Dermatoses; Hand Dermatoses; Humans; Immunosuppressive Agents; Male; Middle Aged; Tacrolimus; Treatment Outcome

Hand and foot eczema is a chronic skin disorder. Although topical corticosteroids are often used to control the predominant symptoms of the disease, the chronicity of the condition increases the risk of long-term adverse effects. A safer alternative is needed.. To evaluate the safety and efficacy of tacrolimus ointment 0.1% in hand and/or foot eczema.. Twenty-five adults applied tacrolimus ointment 0.1% to affected areas three times daily for 8 weeks and were followed for 2 additional weeks.. Except for vesiculation, compared with baseline there were significant improvements in erythema, scaling, induration, fissuring, composite severity, and pruritus (p<0.007). Two weeks after discontinuing treatment, significant improvement in scaling and composite severity (p<0.03) persisted, whereas erythema, induration, vesiculation, fissuring, and pruritus had returned to pre-treatment levels.. Tacrolimus ointment 0.1% is a promising corticosteroid alternative for hand/foot eczema.

Topics: Administration, Topical; Adult; Eczema; Female; Foot Dermatoses; Hand Dermatoses; Humans; Immunosuppressive Agents; Male; Middle Aged; Pilot Projects; Statistics, Nonparametric; Tacrolimus; Treatment Outcome

Dyshidrotic palmoplantar eczema is a frequent disease often running a chronic relapsing course. Topical glucocorticosteroids form the mainstay of therapy, and alternatives are urgently warranted.. This study was performed to compare the efficacy of tacrolimus (FK506) 0.1% ointment and mometasone furoate 0.1% ointment in the treatment of dyshidrotic palmoplantar eczema.. Sixteen patients were included in the study after a randomized, observer-blind, intrapersonal comparison protocol. After a 2-week washout period, the active treatment phase amounted to 4 weeks with twice-daily topical application of test substances and additional use of emollients at will. Thereafter, patients were monitored at weekly intervals up to 8 weeks.. The dyshidrotic area and severity index showed a more than 50% reduction of baseline values after 2 weeks of active treatment both for FK506 (P =.003) and mometasone furoate (P =.022) in palmar areas. After active treatment, a nonsignificant increase in the dyshidrotic area and severity index was seen with FK506 treated areas. Fourteen of 16 patients had recurring symptoms requiring further therapy within 3 weeks after the active treatment phase.. Treatment with FK506 offers the possibility for rotational therapy with mometasone furoate in long-standing cases of chronic dyshidrotic palmar eczema.

Topics: Administration, Cutaneous; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Eczema, Dyshidrotic; Female; Foot Dermatoses; Glucocorticoids; Hand Dermatoses; Humans; Immunosuppressive Agents; Male; Middle Aged; Mometasone Furoate; Pregnadienediols; Severity of Illness Index; Single-Blind Method; Tacrolimus; Treatment Outcome

Topics: Aged; Female; Foot Dermatoses; Humans; Immunosuppressive Agents; Lichen Planus; Skin Ulcer; Tacrolimus

Linear localized scleroderma is a variant of localized scleroderma characterized by linear bands and sclerotic plaques of the skin, which can result in contractures, muscle atrophy and debilitating deformities. The etiology remains unknown and no specific therapy is available. Regimens combining pulsed high-dose corticosteroids with methotrexate therapy seem promising. Our patient responded well to intravenous prednisolone (500 mg/d) for 3 consecutive days monthly combined with an oral dose of methotrexate of (15 mg/wk).

Topics: Administration, Topical; Anti-Inflammatory Agents; Autoantibodies; Biopsy; Diagnosis, Differential; Drug Administration Schedule; Drug Therapy, Combination; Female; Foot Dermatoses; Humans; Immunosuppressive Agents; Methotrexate; Middle Aged; Prednisolone; Pulse Therapy, Drug; Scleroderma, Localized; Skin; Tacrolimus

Ulcerative lichen planus of the sole is a rare variant of lichen planus, characterized by chronic painful disabling ulceration of the soles. Despite many treatment modalities used to treat ulcerative lichen planus, it is still considered a resistant disease. We report a Saudi female patient with ulcerative lichen planus of the soles resistant to many systemic and topical agents. We used topical tacrolimus 0.1% ointment with excellent response and complete healing in a few weeks as well as good maintenance during a follow-up period of more than 2 years.

Topics: Administration, Cutaneous; Aged; Female; Foot; Foot Dermatoses; Foot Ulcer; Humans; Immunosuppressive Agents; Lichen Planus; Skin; Tacrolimus

Topics: Adult; Dermatologic Agents; Emollients; Female; Foot Dermatoses; Humans; Lichenoid Eruptions; Tacrolimus

Metoprolol, a widely prescribed beta-adrenergic receptor blocker, has occasionally been associated with a diversity of cutaneous reactions. We present a 79-year-old male patient with erosive lichen planus (LP) on the feet and hands who was successfully treated with topical tacrolimus. Six months after the lesions had been cured the patient received the beta-receptor blocker metoprolol for the treatment of hypertonus. Within only 2 weeks of metoprolol intake the erosive lesions on the palms and feet recurred. After discontinuation of the drug and repetitive topical treatment with tacrolimus a complete remission of the lesions could be achieved. The recurrence of erosive LP probably secondary to metoprolol and the therapeutic success of topical tacrolimus in the treatment of LP are discussed.

Topics: Administration, Topical; Adrenergic beta-Antagonists; Aged; Foot Dermatoses; Humans; Immunosuppressive Agents; Lichen Planus; Male; Metoprolol; Tacrolimus

Topics: Calcineurin Inhibitors; Eczema; Foot Dermatoses; Hand Dermatoses; Humans; Immunosuppressive Agents; Tacrolimus